IQVIA (NYSE:IQV) Issues Earnings Results

IQVIA (NYSE:IQV) announced its quarterly earnings data on Tuesday. The medical research company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08, FiscalAI reports. The company had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter last year, the firm posted $3.00 EPS.

IQVIA Price Performance

Shares of NYSE:IQV opened at $280.89 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA has a 52 week low of $154.50 and a 52 week high of $282.98. The firm has a market cap of $46.23 billion, a PE ratio of 34.85, a price-to-earnings-growth ratio of 2.46 and a beta of 1.17. The firm’s fifty day moving average is $263.36 and its 200-day moving average is $209.63.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company’s stock.

More IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA reported adjusted earnings of $3.34 per share, ahead of the $3.24-$3.26 analyst consensus, while revenue rose 8% year over year to $4.43 billion, exceeding expectations of approximately $4.37 billion. IQVIA Holdings Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company’s R&D Solutions segment helped drive the quarterly beat. Clinical bookings reportedly reached their strongest level since 2022, suggesting healthier demand and potential support for future revenue growth. IQVIA Gains as R&D Solutions Drive Q3 Beat
• Neutral Sentiment: IQVIA expects 2026 revenue of $17.35 billion to $17.50 billion, compared with the FactSet consensus estimate of $17.41 billion. The range is broadly in line with expectations, providing limited evidence of a major outlook upgrade. IQVIA Expects 2026 Revenue of $17.35 Billion to $17.50 Billion
• Negative Sentiment: Despite the earnings and revenue beats, shares moved lower before the market opened. The likely concern is that management’s forward revenue outlook was not meaningfully above expectations, prompting some investors to take profits after the stock’s substantial recent gains. IQVIA Q3 Adjusted Earnings and Revenue Rise

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IQV shares. Deutsche Bank Aktiengesellschaft reduced their target price on shares of IQVIA from $191.00 to $179.00 in a research report on Thursday, October 15th. Evercore lifted their price objective on IQVIA from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Morgan Stanley upped their target price on IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, September 17th. Jefferies Financial Group increased their target price on IQVIA from $220.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, BMO Capital Markets raised their price target on IQVIA from $270.00 to $305.00 in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $278.75.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.